Inflammation & Allergy-Drug Targets

(Formerly Current Drug Targets - Inflammation & Allergy)

Kurt S Zaenker
Institute of Immunology and Experimental Oncology
University Witten/Herdecke
Stockumerstraße 10
Witten, 58448
Germany

Back

Interleukin-25 Negatively Controls Pathogenic Responses in the Gut

Author(s): Eleonora Franze, Angelamaria Rizzo, Roberta Caruso, Francesco Pallone and Giovanni Monteleone

Affiliation: Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier, 1, 00133 Roma, Italy.

Keywords: IL-25, IBD, Th1, Th17, TNF-, IFN-, NK cells, gut, gut immune, cytokines

Abstract:

Although interleukin-25 (IL-25) has been traditionally considered as a cytokine involved in T helper (Th) 2 cell-associated allergic diseases and host defence against helminthic parasites, recent studies have shown that IL-25 exerts negative effects on the initiation and progression of Th1/Th17-mediated pathologies. This later function of IL-25 is particularly evident at the gut level, where IL-25 could contribute to attenuate tissue-damaging immune responses. These new and exciting pre-clinical observations suggest that therapeutic interventions aimed at enhancing IL-25 activity could be useful in the management of patients with chronic gut inflammation.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 10
ISSUE: 3
Page: [187 - 191]
Pages: 5
DOI: 10.2174/187152811795564028